TScan Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
TScan Therapeutics, Inc. (Nasdaq: TCRX) will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on September 14, 2022, at 12:55 p.m. ET in New York, NY. The event will be webcasted, and an archived replay will be available on the company’s website for 30 days. TScan focuses on T cell receptor (TCR) engineered therapies for cancer, with lead candidates TSC-100 and TSC-101 targeting hematologic malignancies. Their ImmunoBank aids in developing customized therapies for various solid tumors.
- None.
- None.
WALTHAM, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that management will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference being held at the Sheraton New York in New York, NY on Wednesday, September 14, 2022 at 12:55 p.m. ET.
A webcast of the fireside chat will be available on the “Events and Presentations” section of the Company’s website at www.ir.tscan.com. An archived replay of the webcast will be available on the Company’s website for 30 days following the event.
About TScan Therapeutics, Inc.
TScan is a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after hematopoietic stem cell transplantation. The Company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to build its ImmunoBank, the Company’s repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types in order to provide customized multiplexed TCR-T therapies for patients with a variety of solid tumors.
Contacts:
Heather Savelle
TScan Therapeutics, Inc.
VP, Investor Relations
857-399-9840
hsavelle@tscan.com
Joyce Allaire
LifeSci Advisors, LLC
Managing Director
617-435-6602
jallaire@lifesciadvisors.com
FAQ
What is the date and time of TScan Therapeutics' participation in the Morgan Stanley conference?
Where can I watch the webcast of TScan Therapeutics' fireside chat?
What therapies is TScan Therapeutics developing?
How long will the archived replay of TScan Therapeutics' webcast be available?
